参考文献/References:
[1] 顾蔚萍,朱霖.中国放射性药物发展战略研究.北京:原子能出版社,2006:16-18.
[2] 王荣福.放射性正电子药物在肿瘤中的应用研究.实用肿瘤杂志,2006,21(1):92-94.
[3] Mullani NA,Herbst RS,O’Neil RG,et al.Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG up-take:a comparison with 15O-labeled water-measured blood flow.J Nucl Med,2008,49(4):517-523.
[4] Ryu EK,Choe YS,Kim DH,et al.In vitro metabolism studies of 18F-labeled 1-phenylpiperazine using mouse liver S9 fraction.Nucl Med Biol,2006,33(2):165-172.
[5] Tan PZ,Baldwin RM,Van Dyck CH,et al.Characterization of radioactive metabolites of 5-HT2A receptor PET ligand 18F-altanserin in human and rodent.Nucl Med Biol,1999,26(6):601-608.
[6] Shetty HU,Zoghbi SS,Liow JS,et al.Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand 11C-PE2I.Eur J Nucl Med Mol Imaging,2007,34(5):667-678.
[7] Yang W,Mou T,Peng C,et al.Fluorine-18 labeled galactosyl-neogly-coalbumin for imaging the hepatic asialoglycoprotein receptor.Bioorg Med Chem,2009,17(21):7510-7516.
[8] Lucatelli C,Honer M,Salazar JF,et al.Synthesis,radiolabeling,in vitro and in vivo evaluation of 18F-FPECMO as a positron emission tomography radioligand for imaging the metabotropic glutamate receptor subtype 5.Nucl Med Biol,2009,36(6):613-622,
[9] McCarron J,Zoghbi SS,Shetty HU,et al,Synthesis and initial evaluation of 11C-(R)-RWAY in monkey-a new,simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET.Eur J Nucl Med Mol Imaging,2007,34(10):1670-1682.
[10] Osman S,Lundkvist C,Pike VW,et al.Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand radioligand,[carbony-11C] WAY-100635-explanation of high signal contrast in PET and an aid to biomathe-matical modelling.Nucl Med Biol,1998,25(3):215-223.
[11] Watabe H,Channing MA,Der MG,et al.Kinetic analysis of the 5-HT2A ligand 11C-MDL 100,907.J Cereb Blood Flow Metab,2000,20(6):899-909.
[12] Stringer RA,Strain-Damerell C,Nicklin P,et al.Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.Drug Metab Dispos,2009,37(5):1025-1034.
[13] Tang JC,Yang H,Song XY,et al.Inhibition of cytochrome P450 enzymes by rhein in rat liver microsomes.Phytother Res,2009,23(2):159-164.
[14] Shaffer CL,Langer CS.Metabolism of a 14C/3H-labeled GABAA receptor partial agonist in rat,dog and human liver microsomes:evaluation of a dual-radiolabel strategy.J Pharm Biomed Anal,2007,43(4):1195-1205.
[15] Ma Y,Kiesewetter DO,Lang L,et al.Determination of 18F-FCWAY,18F-FP-TZTP,and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions.Nucl Med Biol,2003,30(3):233-240.
[16] Hasler F,Kuznetsova OF,Krasikova RN, et al.GMP-compliant radiosynthesis of 18F-altanserin and human plasma metabolite studies.Appl Radiat Isot,2009,67(4):598-601.
[17] Jang DP,Lee SH,Park CW,et al.Effects of fluoxetine on the rat brain in the forced swimming test:a 18F-FDG micro-PET imaging study.Neurosci Lett,2009,451(1):60-64.
[18] Idbaih A,Burlet A,Adle-Biassette H,et al.Altered cerebral glucose metabolism in an animal model of diabetes insipidus:a micro-PET study.Brain Res,2007,1158:164-168.
[19] Conti PS,Bading JR,Mouton PP,et al.In vivo measurement of cell proliferation in canine brain tumor using 11C-labeled FMAU and PET.Nucl Med Biol,2008,35(1):131-141.
[20] Bading JR,Shahinian AH,Vail A,et al.Pharmacokinetics of the thymidine analog 2’-fluoro-5-methyl-1-beta-D-arabinofura-nosylu-racil (FMAU) in tumor-bearing rats.Nucl Med Biol,2004,31(4):407-418.
[21] Bading JR,Shahinian AH,Bathija P,et al.Pharmacokinetics of the thymidine analog 2’-fluoro-5’-[14C]-methyl-1-β-D-arabinofuranosy-luracil(14C-FMAU)in rat prostate tumor cells.Nucl Med Biol,2000,27(4):361-368.
[22] Solon EG,Schweitzer A,Stoeckli M,el al.Autoradiography,MALDI-MS,and SIMS-MS imaging in pharmaceutical discovery and development.AAPSJ,2010,12(1):11-26.
[23] Dedeurwaerdere S,Gregoire MC,Vivash L,et al.In vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat.Eur J Nucl Med Mol Imaging,2009,36(6):958-965.
[24] Kikuchi T,Okamura T,Zhang MR,et al.In vivo evaluation of N-[18F] fluoroethylpiperidin-4ylmethyl acetate in rats compared with MP4A as a probe for measuring cerebral acetylcholinesterase activity.Synapse,2009,64(3):209-215.
[25] Gillings N.A restricted access material for rapid analysis of 11C-labeled radiopharmaceuticals and their metabolites in plasma.Nucl Med Biol,2009,36(8):961-965.
[26] Ma S, Zhu M.Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites.Chem Biol Interact,2009,179(1):25-37.
[27] Gray MJ,Chang D,Zhang Y,et al.Development of liquid chio-matography/mass spectrometry methods for the quantitative analysis of herbal medicine in biological fluids:a review.Biomed Chro-matogr,2010,24(1):91-103.
[28] 乔晋萍,韩梅,朱霖.Radio-LC-MS及其在放射性药物研究中的应用.质谱学报,2008,29(1):60-64.
[29] Boswell CA,McQuade P,Weisman GR,et al.Optimization of labeling and metabolite analysis of copper-64-labeled azamacro-cyclic chelators by radio-LC-MS.Nucl Med Biol,2005,32(1):29-38.
[30] Houle S,DaSilva JN,Wilson AA.Imaging the 5-HT1A receptors with PET:WAY-100635 and analogues.Nucl Med Biol,2000,27(4):361-368.
[31] Zoghbi SS,Shetty HU,Ichise M,et al.PET imaging of the dopamine transporter with 18F-FECNT:a polar radiometabolite confounds brain radioligand measurements.J Nucl Med,2006,47(3):520-527.
[32] Mitterhauser M,Wadsak W,Wabnegger L, et al.Biological evaluation of 2’-[18F] fluoroflumazenil ([18F] FFMZ),a potential GABA receptor ligand for PET.Nucl Med Biol,2004,31(2):291-295
[33] Roivainen A,Nägren K,Hirvonen J,et al.Whole-body distribution and metabolism of[N-methyl-11C] (R)-1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide in humans; an imaging agent for in vivo assessment of peripheral benzodiazepine receptor activity with poeitron emission tomography.Eur J Nucl Med Mol Imaging,2009,36(4):671-682.
[34] Bier D,Holschbach MH,Wutz W,et al.Metabolism of the A1 adenosine receptor positron emission tomography ligand[18F] 8-cyclopentyl-3-(3-ftuoropropyl)-1-propylxanthine ([18F] CPFPX) in rodents and humans.Drug Metab Dispoe,2006,34(4):570-576.
[35] Hǒltke C,Law MP,Wagner S,et al.PET-compatible endothelin receptor radioligands:synthesis and first in vitro and in vivo studies.Bioorg Med Chem,2009,17(20):7197-7208.
[36] Luurtsema G,Schuit RC,Takkenkamp K,et al.Peripheral metabolism of 18F-FDDNP and cerebral uptake of its labelled metabolites.Nucl Med Biol,2008,35(8):869-874.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[8]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[9]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[10]张巍,杨珂.18f正电子放射性药物生产及使用中医务人员的受照剂量研究[J].国际放射医学核医学杂志,2015,39(5):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
zhang wei,yang ke..the research of radiation dose of 18f-fdg to pet/ct related personnel[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
[11]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]